|
Leucovorin for the Treatment of 5 q Minus Syndrome Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Leucovorin for the Treatment of 5 q Minus Syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Leucovorin for the Treatment of 5 q Minus Syndrome Clinical research trials and Leucovorin for the Treatment of 5 q Minus Syndrome medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Leucovorin for the Treatment of 5 q Minus Syndrome. Leucovorin for the Treatment of 5 q Minus Syndrome Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Leucovorin for the Treatment of 5 q Minus Syndrome clinical trial. Participants frequently get the best healthcare available for their Leucovorin for the Treatment of 5 q Minus Syndrome condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Leucovorin for the Treatment of 5 q Minus Syndrome  Leucovorin for the Treatment of 5 q Minus Syndrome
Leucovorin for the Treatment of 5 q Minus Syndrome
For Condition: 5q Minus Syndrome,Myelodysplastic Syndrome
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: The 5 q minus syndrome is a condition that occurs due to a missing segment of chromosome 5 in the normal genetic make-up of the cells responsible for forming blood cells. The condition causes patients to have the inability to make blood normally. Many patients with this syndrome need transfusions of red blood cells, platelets, and/or white blood cells. Low levels of platelets may cause the patient to bleed easily and low levels of whit blood cells make the patient susceptible to infections. A small number of patients with 5 q minus syndrome develop leukemia, which is often untreatable with chemotherapy. Researchers believe that one of the genes missing in 5 q minus syndrome is the gene responsible for making folic acid active in the body. Folic acid is a vitamin required for normal blood production. The purpose of this study to test the effectiveness of a drug called leucovorin for the treatment of 5 q minus syndrome. Leucovorin is an active form of the vitamin folic acid that does not require the missing genes to activate it. Patients participating in this study may or may not improve with leucovorin treatment. However, the study will improve researchers understanding of the disease and may lead other potential therapies for the disease.
Details: The objective of this protocol is to determine whether leucovorin treatment can normalize hematopoietic cell growth and differentiation in patients with 5q- syndrome which may lack the gene for dihydrofolate reductase enzyme.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: All patients 18 years old and older with RA, RARS and RAEB who have a 5q deletion as their sole cytogenetic abnormality who require transfusion support with blood defined as needing at least one unit of packed red blood cells per month for greater than or equal to 2 months and/or thrombocytopenia defined as a platelet count less than 50,000, and/or severe neutropenia (absolute neutrophil count less than 500) are eligible, including patients that had been treated with chemotherapy or experimental agents such as retinoids, phenylbutyrate, amifostine, Vitamin D, ATG or hematopoietic growth factors. Patients must not be transforming to acute leukemia (greater than 20% blasts in marrow aspirate). Patients must not have had treatment with growth factors or any other experimental drug within 4 weeks prior to entry on protocol. Patients must not have an ECOG performance status greater than 2. Patients must not have an active uncontrolled infection. No patients for whom bone marrow transplant is indicated as primary therapy. Must be able to give informed consent. Patients must not be HIV positive. Patients must not be pregnant.
Total Enrollment: 14
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980101; 98-CC-0101
Study Start Date: April 24, 1998
Record last reviewed: July 29, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004997
Other Myelodysplastic Syndrome Studies:
1. Leucovorin for the Treatment of 5 q Minus Syndrome
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Leucovorin for the Treatment of 5 q Minus Syndrome
|
|
|
|
|
|
|
|
